skin cancer
Castle Biosciences to Expand GI Offerings With Previse Merger, Discontinue Mental Health PGx Test
Premium
The company reported 21 percent year-over-year revenue growth for the first quarter, driven largely by TissueCypher Barrett's esophagus test results deliveries.
Gestalt, Primaa Partner on AI-Based Testing for Skin Cancer
The firms said that they will integrate Primaa's skin cancer testing algorithms with Gestalt's PathFlow digital pathology software platform.
Castle Biosciences Q4 Revenues up 31 Percent
The company saw a boost in testing volume in the fourth quarter, but not across all its assays, while full-year revenues grew 51 percent.
Akoya Biosciences Licenses Early-Stage Melanoma Test From NeraCare
The exclusive license agreement builds on an existing research collaboration between the companies to develop assays for skin cancer using Akoya's immunofluorescence platform.
Castle Biosciences Q3 Revenues up 39 Percent
The company saw growth across its melanoma, squamous cell carcinoma, Barrett's esophagus, and pharmacogenomics tests.
Oct 31, 2024
Aug 5, 2024
Castle Biosciences Q2 Revenues Jump 74 Percent
Apr 17, 2024
DermTech Receives Delisting Warning From Nasdaq
May 9, 2022
Castle Biosciences Q1 Revenues Grow 18 Percent
May 4, 2022
DermTech Posts 48 Percent Jump in Q1 Revenues
Feb 28, 2022